HC Wainwright Comments on FibroBiologics Q1 Earnings

FibroBiologics, Inc. (NASDAQ:FBLG) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of FibroBiologics in a report issued on Tuesday, April 1st. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of ($0.11) for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for FibroBiologics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS and FY2029 earnings at ($0.59) EPS.

Several other equities analysts have also weighed in on FBLG. D. Boral Capital reiterated a “buy” rating and issued a $16.00 target price on shares of FibroBiologics in a report on Tuesday. Rodman & Renshaw started coverage on FibroBiologics in a report on Thursday, December 12th. They issued a “buy” rating and a $12.00 price objective on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $13.00.

FibroBiologics Price Performance

Shares of FBLG opened at $0.94 on Wednesday. FibroBiologics has a 12-month low of $0.86 and a 12-month high of $13.59. The firm has a 50-day moving average price of $1.26 and a 200 day moving average price of $2.13.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings data on Monday, March 31st. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01.

Institutional Investors Weigh In On FibroBiologics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Intech Investment Management LLC acquired a new stake in FibroBiologics in the 4th quarter valued at approximately $25,000. Virtu Financial LLC purchased a new stake in shares of FibroBiologics in the 4th quarter valued at $30,000. The Manufacturers Life Insurance Company acquired a new position in FibroBiologics during the 3rd quarter worth about $32,000. Jane Street Group LLC purchased a new position in FibroBiologics during the 3rd quarter valued at about $37,000. Finally, Raymond James Financial Inc. acquired a new position in FibroBiologics in the 4th quarter valued at about $37,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.